



Attorney's Docket No.: 07039-220001

Sector  
#4  
AA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lieping Chen

Art Unit : 1635

Serial No. : 09/649,108

Examiner : Unknown


Filed : August 28, 2000

Title : B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE

**BOX MISSING PARTS**

Commissioner for Patents

Washington, D.C. 20231



RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

In response to the Notice to File Missing Parts of Application under 37 CFR §1.53(b) mailed October 25, 2000 (copy enclosed), applicant as a small entity submits herewith the following:

- ☒ Check in payment of \$65 surcharge for filing the declaration on a date later than the filing date of the application;
- ☒ Combined Declaration and Power of Attorney in compliance with 37 CFR §1.63; and
- ☒ Other: Sequence Listing, Statement Under 37 CFR §1.821(f), and diskette.

Intended  
as AA

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Dec. 15, 2000

Date of Deposit

Paula T. Romeo

Signature

PAULA T. ROMEO

Typed or Printed Name of Person Signing Certificate


Applicant : Lieping Chen  
Serial No. : 09/649,108  
Filed : August 28, 2000  
Page : 2

Attorney's Docket No.: 07039-220001

It is understood that this perfects the application and no additional papers or filing fees are required. Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: December 15, 2000



Stuart Macphail, Ph.D.  
Reg. No. 44,217

*Charles J. Boudreau*  
Reg. No. 42,350

Fish & Richardson P.C.  
45 Rockefeller Plaza, Suite 2800  
New York, NY 10111  
Telephone: (212) 765-5070  
Facsimile: (212) 258-2291

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lieping Chen  
Serial No. : 09/649,108  
Filed : August 28, 2000  
Title : B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE

Art Unit : 1635  
Examiner : Unknown



Commissioner for Patents  
Washington, D.C. 20231  
**BOX MISSING PARTS**

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT


Please correct the Filing Receipt for the above-referenced application to include the name and residence of the inventor, *i.e.*, **Lieping Chen, Rochester, MN.**

Please supply a corrected Filing Receipt to the undersigned with respect to this application. A copy of the original Filing Receipt showing the desired changes in red ink is attached for your convenience.

No fee is believed to be due. If, however, there are any charges or credits, please apply them to Deposit Account No. 06-1050.

Respectfully submitted,

Date: December 15, 2000

  
Stuart Macphail, Ph.D.  
Reg. No. 44,217

*Charles J. Boudreau*  
Reg. No. 42,350

Fish & Richardson P.C.  
45 Rockefeller Plaza, Suite 2800  
New York, NY 10111  
Telephone: (212) 765-5070  
Facsimile: (212) 258-2291  
30031561.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Dec. 15, 2000  
Date of Deposit  
Paula T. Romeo  
Signature  
PAULA T. ROMEO  
Typed or Printed Name of Person Signing Certificate



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

Page 1 of 3

MS  
SY

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/649,108	08/28/2000	1635	597	07039-220001	24	48	1

Mark S Ellinger Phd  
Fish & Richardson PC  
60 South Sixth Street 3300 Dain Rauscher Plaza  
Minneapolis, MN 55402

## FILING RECEIPT

RECEIVED	*OC000000005503241*
OCT 31 2000	
PRACTICE SYSTEMS	

Date Mailed: 10/25/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) Lieping Chen, Rochester, MN

## Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/451,291 11/30/1999

## Foreign Applications

If Required, Foreign Filing License Granted 10/25/2000

\*\* SMALL ENTITY \*\*

## Title

B7-h1-a novel immunoregulatory molecule

## Preliminary Class

514

Docketed By Practice Systems

Correct Filing ReceiptDue date: 11/25/00Initials: speculation

Docketed By Billing Secretary

Due Date: 11/25/00Deadline: 11/25/00Initials: DSR

Data entry by : SASFAI, DAVID

Team : OIPE

Date: 10/25/2000



**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231






## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/649,108	08/28/2000		07039-220001

Mark S Ellinger Phd  
Fish & Richardson PC  
60 South Sixth Street 3300 Dain Rauscher Plaza  
Minneapolis, MN 55402



## FORMALITIES LETTER



\*OC000000005503242\*

Date Mailed: 10/25/2000

## NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

*Filing Date Granted*

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).


- The oath or declaration is missing.  
*A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.*
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.
- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason (s):
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required under 37 CFR 1.821(e).
  - Applicant must provide:
    - A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-1123
- For CRF Submission Help, call (703) 308-4212
- PatentIn Software Program Support
  - - For Technical Assistance, call (703) 287-0200
  - - To Purchase PatentIn Software, call (703) 306-2600

12/26/2000 JADD01 00000033 09649108 65.00 01 FC:205

- The balance due by applicant is \$ 65.



*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE